REFERENSI

1. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et.al.

Pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. Jakarta: PB
PERKENI; 2015. h. 6-42, 51.
2. Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of
diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018; 42: S10-
S15.
3. Kshanti IAM, Wibudi A, Sibarani RP, Saraswati MR, Dwipayana IMR,
Mahmudji HA, et.al. Pedoman pemantauan glukosa darah mandiri. Jakarta: PB
PERKENI; 2019. h. 1.
4. Kementerian Kesehatan RI. Hasil utama RISKESDAS 2018. Jakarta:
Kementerian Kesehatan RI; 2018. h. 66, 73-5.
5. American Diabetes Association. Standards of medical care in diabetes. 2014.
Diabetes Care. 2014; 37(1): S14-79.
6. Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of
diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018; 42: S10-
S15.
7. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for
the treatment of type 2 diabetes melitus. Diabetes. 2009; 59(4): 773-95.
8. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et.al.
Differentiation of diabetes by pathophysiology, natural history, and prognosis.
Diabetes. 2017; 66; 241-55.
9. AACE/ACE. Statement on the use of hemoglobin A1c for the diagnosis of
diabetes. Endocr Pract. 2010; 16(2): 155-6.
10. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA,
et.al. Consensus statement by the American Association of Clinical
Endocrinologists and American College of Endocrinology on the comprehensive
type 2 diabetes management algorithm – 2019 executive summary. Endocr Pract.
2019; 25(1): 69-100.
11. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin.
Diabetologia. 2017; 60: 1577-85.
12. Gong L, Goswami, S, Giacomini KM, Altman RB, Klein TE. Metformin
pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics.
2012; 22(11): 820-7.
13. Liang X, Giacomini KM. Transporters involved in metformin pharmacokinetics
and treatment response. J Pharm Sci. 2017; 106: 2245-50.
14. Reasner C, Olansky L, Seck TL, Wiliams-Herman DE, Chen M, Terranella
L,et.al. The effect of initial therapy with the fixed-dose combination of sitagliptin
and metformin compared with metformin monotherapy in patients with type 2
diabetes mellitus. Diabetes Obes Metab. 2011; 13: 644-52.
15. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin
add-on to metformin in type 2 diabetes inadequately controlled with metformin:
A randomized, double-blind, placebo-controlled 102-week trial. BMC Med.
2013; 11: 43.
16. Zeitler P, Hirst K, Linder B, Copeland K, Arslanian S, Nathan DM, et.al. A
clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J
Med. 2012; 366(24): 2247-56.
17. Dinaryanti P, Fudholi A, Andayani TM. Analisis biaya dan efektivitas terapi
pasien diabetes melitus tipe 2 rawat jalan di RSUD Sleman Yogyakarta. Jurnal
Manajemen dan Pelayanan Farmasi. 2012; 2(1): 14-9.
18. Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality
of life. World J Diabetes. 2017; 8(4): 120-9.
19. Esteghamati A, Ghasemiesfe M, Mousavizadeh M, Noshad S, Nakhjvani M.
Pioglitazone and metformin are equally effective in reduction of chemerin in
patients with type 2 diabetes. J Diabetes Invest. 2014; 5: 327-32.
20. Leighton E, Sainsbury CA, Jones GC. A practical review of c-peptide testing in
diabetes. Diabetes Ther. 2017; 8: 475-87.
21. Kelsey M, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler PS, et.al.
Presentation and effectiveness of early treatment of type 2 diabetes in youth:
Lessons from the TODAY study. Pediatr Diabetes. 2015; 17(3): 212-21.
22. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF.
Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for the type 2
diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66(5): 446-56.
23. Romanelli RJ, Chung S, Pu J, Nimbal V Zhao B, Palaniappan L. Comparative
effectiveness of early versus delayed metformin in the treatment of type 2
diabetes. Diabetes Res Clin Pract. 2015; 108(1): 170-8.